D–R group (n = 29) | P–R group (n = 30) | difference (95% CI) | P value | |
---|---|---|---|---|
Respiratory adverse events, n (%) | 1 (3.4%) | 8 (26.7%) | 23.3% (6.2 to 40.5%) | 0.026 |
Cardiovascular adverse events, n (%) | 6 (20.7%) | 4 (13.3%) | 7.4% (− 11.7 to 26.5%) | 0.506 |
Hypertension, n (%) | 2 (6.9%) | 0 (0%) | 6.9% (− 2.3 to 16.1%) | 0.237 |
Hypotension, n (%) | 2 (6.9%) | 3 (10%) | 3.1% (− 11.1 to 17.3%) | 1.000 |
Bradycardia, n (%) | 2 (6.9%) | 1 (3.3%) | 3.6% (− 7.6 to 14.8%) | 0.612 |